參考文獻/References:
[1] 楊金杰.微骨折術聯合關節(jié)腔內注射富血小板血漿治療小面積距骨骨軟骨損傷[J].中國修復重建外科雜志,2020,34(1):53-56.
[2] 祝俊山,馮秀珍,莊汝杰.富血小板血漿治療足踝外科相關疾病的研究進展[J].中國全科醫(yī)學,2018,21(23):2886-2890.
[3] JAZZO S F,SCRIBNER D,SHAY S,et al.Patient-reported outcomes following platelet-rich plasma injections in treating osteochondral lesions of the talus:a critically appraised topic[J].J Sport Rehabil,2018,27(2):177-184.
[4] HOGAN M V,HICKS J J,CHAMBERS M C,et al.Biologic adjuvants for the management of osteochondral lesions of the talus[J].J Am Acad Orthop Surg,2019,27(3):e105-e111.
[5] MOATSHE G,MORRIS E R,CINQUE M E,et al.Biological treatment of the knee with platelet-rich plasma or bone marrow aspirate concentrates[J].Acta Orthop,2017,88(6):670-674.
[6] 周耀東,牛德剛.富血小板血漿治療骨性關節(jié)炎的研究觀察[J].山東醫(yī)學高等專科學校學報,2020,42(4):319-320.
[7] ELIAS I,ZOGA A C,MORRISON W B,et al.Osteochondral lesions of the talus:localization and morphologic data from 424 patients using a novel anatomical grid scheme[J].Foot Ankle Int,2007,28(2):154-161.
[8] 張成昌,楊柳,段小軍.距骨骨軟骨損傷的治療研究進展[J].中華關節(jié)外科雜志(電子版),2019,13(4):466-472.
[9] LOOZE C A,CAPO J,RYAN M K,et al.Evaluation and management of osteochondral lesions of the talus[J].Car-tilage,2017,8(1):19-30.
[10] BOFFA A,PREVITALI D,DI LAURA FRATTURA G,et al.Evidence on ankle injections for osteochondral lesions and osteoarthritis:a systematic review and meta-analysis[J].Int Orthop,2021,45(2):509-523.
[11] 謝盼盼,葉方,葉積飛.距骨軟骨損傷的診療進展[J].中國骨傷,2018,31(9):880-884.
[12] LE A D K,ENWEZE L,DEBAUN M R,et al.Current clinical recommendations for use of platelet-rich plasma[J].Curr Rev Musculoskelet Med,2018,11(4):624-634.
[13] 常樂,宋琳娜,馮世波.人工全膝關節(jié)置換術聯合富血小板血漿對創(chuàng)傷性膝關節(jié)炎恢復的影響[J].局解手術學雜志,2020,29(8):640-644.
[14] ZHU Y,YUAN M,MENG H Y,et al.Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis:a review[J].Osteoarthritis Cartilage,2013,21(11):1627-1637.
[15] KENNEDY M I,WHITNEY K,EVANS T,et al.Platelet-rich plasma and cartilage repair[J].Curr Rev Musculoskelet Med,2018,11(4):573-582.
[16] MARTíNEZ-MARTíNEZ A,RUIZ-SANTIAGO F,GARCíA-ESPINOSA J.Platelet-rich plasma:myth or reality?[J].Radiologia(Engl Ed),2018,60(6):465-475.
[17] HULSOPPLE C.Musculoskeletal therapies:musculoskeletal injection therapy[J].FP Essent,2018,470:21-26.
[18] YAUSEP O E,MADHI I,TRIGKILIDAS D.Platelet rich plasma for treatment of osteochondral lesions of the talus:A systematic review of clinical trials[J].J Orthop,2020,18:218-225.
[19] DOMBROWSKI M E,YASUI Y,MURAWSKI C D,et al.Conservative management and biological treatment strategies:proceedings of the international consensus meeting on cartilage repair of the ankle[J].Foot Ankle Int,2018,39(1 suppl):9S-15S.
[20] G?MELI G,KARAKAPLAN M,G?MELI C A,et al.Clinical effects of platelet-rich plasma and hyaluronic acid as an additional therapy for talar osteochondral lesions treated with microfracture surgery:a prospective randomized clinical trial[J].Foot Ankle Int,2015,36(8):891-900.
[21] GUNEY A,AKAR M,KARAMAN I,et al.Clinical outcomes of platelet rich plasma(PRP)as an adjunct to microfracture surgery in osteochondral lesions of the talus[J].Knee Surg Sports Traumatol Arthrosc,2015,23(8):2384-2389.
[22] MEI-DAN O,CARMONT M R,LAVER L,et al.Platelet-rich plasma or hyaluronate in the management of osteochondral lesions of the talus[J].Am J Sports Med,2012,40(3):534-541.
[23] HEPPLE S,WINSON I G,GLEW D.Osteochondral lesions of the talus:a revised classification[J].Foot Ankle Int,1999,20(12):789-793.
[24] GU W,LI T, SHI Z,et al.Management of hepple stage v osteochondral lesion of the talus with a platelet-rich plasma scaffold[J/OL].Biomed Res Int,2017,2017[2021-02-21]. https://pubmed.ncbi.nlm.nih.gov/28401159/.
[25] AKPANCAR S,GüL D.Comparison of platelet rich plasma and prolotherapy in the management of osteochondral lesions of the talus:a retrospective cohort study[J].Med Sci Monit,2019,25:5640-5647.
[26] SMYTH N A,MURAWSKI C D,HALEEM A M,et al.Establishing proof of concept:Platelet-rich plasma and bone marrow aspirate concentrate may improve cartilage repair following surgical treatment for osteochondral lesions of the talus[J].World J Orthop,2012,3(7):101-108.
[27] 魏芳遠,曲峰,王顯軍,等.富含血小板血漿通過抑制基質細胞衍生因子-1/CxC趨化因子受體4通路治療距骨軟骨損傷的作用機制[J].中國臨床醫(yī)生雜志,2019,47(7):834-837.
[28] 位付濤,王振.去白細胞富血小板血漿對距骨骨軟骨損傷的療效及機制研究[J].中國修復重建外科雜志,2019,33(5):555-562.
相似文獻/References:
[1]蔣巧玲,郭水潔,葉艷君,等.應用SPECT-CT圖像融合技術評價锝〖99Tc〗-亞甲基二膦酸鹽治療距骨缺血性壞死的臨床療效[J].中醫(yī)正骨,2017,29(02):31.
[2]王建超,胡秀良,苗旭東,等.自體帶骨膜髂骨植骨聯合螺釘內固定治療距骨軟骨損傷[J].中醫(yī)正骨,2019,31(09):71.
[3]吳繁,莊汝杰.后踝關節(jié)撞擊綜合征的診治進展[J].中醫(yī)正骨,2021,33(08):59.
WU Fan,ZHUANG Rujie.Advancement of diagnosis and treatment of posterior ankle impingement syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(09):59.
[4]鄒相杰,陶天奇,蔣逸秋.踝關節(jié)鏡下清理聯合局部微骨折術治療距骨骨樣骨瘤[J].中醫(yī)正骨,2022,34(03):73.
[5]張志偉,賴良鵬,李興華,等.聯合改良雙平面Chevron內踝截骨自體骨軟骨移植術治療HeppleⅤ期距骨骨軟骨損傷的臨床研究[J].中醫(yī)正骨,2022,34(10):38.
ZHANG Zhiwei,LAI Liangpeng,LI Xinghua,et al.A clinical study of intra-articular injection of platelet-rich plasma combined with modified dual-plane Chevron medial malleolar osteotomy and autologous osteochondral transplantation for treatment of Hepple stageⅤosteochondral lesion of the talus[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2022,34(09):38.
[6]徐濤,周明,侯慧銘,等.關節(jié)鏡下帶骨膜髂骨移植聯合富血小板血漿凝膠注射治療HeppleV型距骨骨軟骨損傷[J].中醫(yī)正骨,2024,36(05):76.
[7]劉核達,劉林,黃飛,等.自體富血小板血漿關節(jié)腔注射聯合堅骨膠囊口服在自體骨軟骨移植手術治療HeppleⅤ型距骨骨軟骨損傷中的應用[J].中醫(yī)正骨,2024,36(08):73.